Scientific Evidence

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms

Nov 2023

Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions

Author: Goldberg M, et al.

Publication: Skin

31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Jun 2023

Study data from Castle Biosciences' collaberation with the National Cancer Institutes SEER program registries.

Author: Bailey CN, et al.

Publication: JCO-PO

Asymmetrical pigmented lesion with high clinical suspicion for melanoma

Jun 2023

A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.

Multi-colored lesion with uncertain malignant potential

Jun 2023

Conflicting clinical and histopathological findings are resolved with the use of GEP test results.

Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis

Jun 2023

Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.

Atypical melanocytic proliferation on sensitive preauricular check

Jun 2023

Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.

Abnormally pigmented lesion with uncertain malignant potential

Jun 2023

With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.

Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies

Mar 2023

Independent mulit-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

Author: Dhillon S, et al.

Publication: Archives of Derm Research

The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study

Jan 2023

DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.

Author: Yamamoto M, et al.

Publication: Current Medical Research and Opinion

Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel report

Jan 2023

Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing.

Author: Zakria D, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma

Jan 2023

Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.

Author: Martin B, et al.

Publication: Poster, presented at Winter Clinical Dermatolog conference- Hawaii Jan 13-18 2023

The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can forego sentinel lymph node biopsy

Nov 2022

Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.

Author: Zakria D, et al.

Publication: SKIN: Journal of Cutaneous Melanoma